Compounds
Every entry covers structure, proposed mechanism, the state of the research, regulatory status and what a certificate of analysis should show. 61 compounds, sorted A–Z.
| Compound | Research area | Residues | Highest evidence | Sequence |
|---|---|---|---|---|
| 5-Amino-1MQ | Related non-peptides & cofactors | — | Preclinical (animal and cell studies) | |
| Abaloparatide | Bone & calcium | 34 | Approved drug | 34 residues |
| Afamelanotide | Melanocortin & reproductive | 13 | Approved drug | Ac–SYSNleEHFRWGKPV–NH₂ |
| AOD-9604 | Metabolic & incretin | 16 | Early clinical studies | YLRIVQCRSVEGSCGF–OH |
| ARA-290 (cibinetide) | Tissue repair & signaling | 11 | Early clinical studies | PyrEQLERALNSS–OH |
| Argireline (acetyl hexapeptide-8) | Cosmetic research | 6 | Preclinical (animal and cell studies) | Ac–EEMQRR–NH₂ |
| BPC-157 | Tissue repair & signaling | 15 | Early clinical studies | GEPPPGKPADDAGLV–OH |
| Cagrilintide | Metabolic & incretin | see entry | Late-stage clinical trials | |
| Calcitonin (salmon) | Bone & calcium | 32 | Approved drug | 32 residues |
| Cerebrolysin | Neuropeptides | see entry | Approved drug | |
| CJC-1295 | Growth hormone axis | 29 | Early clinical studies | YADAIFTQSYRKVLAQLSARKLLQDILSR–NH₂ |
| Dihexa | Neuropeptides | see entry | Preclinical (animal and cell studies) | |
| DSIP | Neuropeptides | 9 | Early clinical studies | WAGGDASGE–OH |
| Epitalon | Mitochondrial & ageing | 4 | Early clinical studies | AEDG–OH |
| Exenatide | Metabolic & incretin | 39 | Approved drug | 39 residues |
| Follistatin-344 | Growth hormone axis | see entry | Early clinical studies | |
| FOXO4-DRI | Mitochondrial & ageing | see entry | Preclinical (animal and cell studies) | |
| GHK-Cu | Cosmetic research | 3 | Early clinical studies | GHK–OH |
| GHRP-2 | Growth hormone axis | 6 | Early clinical studies | ANalAWFK–NH₂ |
| GHRP-6 | Growth hormone axis | 6 | Early clinical studies | HWAWFK–NH₂ |
| Glutathione | Related non-peptides & cofactors | 3 | Early clinical studies | ECG–OH |
| Gonadorelin | Melanocortin & reproductive | 10 | Approved drug | PyrHWSYGLRPG–NH₂ |
| Hexarelin | Growth hormone axis | see entry | Early clinical studies | |
| Humanin | Mitochondrial & ageing | 24 | Preclinical (animal and cell studies) | MAPRGFSCLLLLTSEIDLPVKRRA–OH |
| IGF-1 LR3 | Growth hormone axis | 83 | Preclinical (animal and cell studies) | 83 residues |
| Ipamorelin | Growth hormone axis | 5 | Early clinical studies | AibHNalFK–NH₂ |
| Kisspeptin-10 | Melanocortin & reproductive | 10 | Early clinical studies | YNWNSFGLRF–NH₂ |
| KPV | Immune & antimicrobial | 3 | Preclinical (animal and cell studies) | KPV–OH |
| Larazotide | Immune & antimicrobial | 8 | Late-stage clinical trials | GGVLVQPG–OH |
| Liraglutide | Metabolic & incretin | see entry | Approved drug | |
| LL-37 | Immune & antimicrobial | 37 | Early clinical studies | 37 residues |
| Matrixyl (palmitoyl pentapeptide-4) | Cosmetic research | 5 | Preclinical (animal and cell studies) | Hex–KTTKS–OH |
| Mazdutide | Metabolic & incretin | see entry | Late-stage clinical trials | |
| Melanotan II | Melanocortin & reproductive | 7 | Early clinical studies | Ac–NleDHFRWK–NH₂ |
| MK-677 (ibutamoren) | Growth hormone axis | — | Early clinical studies | |
| MOTS-c | Mitochondrial & ageing | 16 | Early clinical studies | MRWQEMGYIFYPRKLR–OH |
| NAD+ | Related non-peptides & cofactors | — | Early clinical studies | |
| Noopept | Neuropeptides | — | Early clinical studies | |
| Oxytocin | Melanocortin & reproductive | 9 | Approved drug | CYIQNCPLG–NH₂ |
| PEG-MGF | Growth hormone axis | see entry | Preclinical (animal and cell studies) | |
| Pinealon | Mitochondrial & ageing | 3 | Preclinical (animal and cell studies) | EDR–OH |
| Pramlintide | Metabolic & incretin | 37 | Approved drug | 37 residues |
| PT-141 (bremelanotide) | Melanocortin & reproductive | 7 | Approved drug | Ac–NleDHFRWK–OH |
| Retatrutide | Metabolic & incretin | see entry | Late-stage clinical trials | |
| Selank | Neuropeptides | 7 | Early clinical studies | TKPRPGP–OH |
| Semaglutide | Metabolic & incretin | see entry | Approved drug | |
| Semax | Neuropeptides | 7 | Early clinical studies | MEHFPGP–OH |
| Sermorelin | Growth hormone axis | 29 | Approved drug | YADAIFTNSYRKVLGQLSARKLLQDIMSR–NH₂ |
| Setmelanotide | Melanocortin & reproductive | 8 | Approved drug | Ac–RCAHFRWC–NH₂ |
| Snap-8 | Cosmetic research | 8 | Preclinical (animal and cell studies) | Ac–EEMQRRAD–NH₂ |
| SS-31 (elamipretide) | Mitochondrial & ageing | 4 | Approved drug | RDmtKF–NH₂ |
| Survodutide | Metabolic & incretin | see entry | Late-stage clinical trials | |
| TB-500 | Tissue repair & signaling | 7 | Preclinical (animal and cell studies) | Ac–LKKTETQ–OH |
| Teriparatide | Bone & calcium | 34 | Approved drug | 34 residues |
| Tesamorelin | Growth hormone axis | 44 | Approved drug | 44 residues |
| Thymalin | Immune & antimicrobial | see entry | Early clinical studies | |
| Thymosin α1 | Immune & antimicrobial | 28 | Approved drug | Ac–SDAAVDTSSEITTKDLKEKKEVVEEAEN–OH |
| Thymosin β4 | Tissue repair & signaling | 43 | Late-stage clinical trials | 43 residues |
| Tirzepatide | Metabolic & incretin | see entry | Approved drug | |
| Triptorelin | Melanocortin & reproductive | 10 | Approved drug | PyrHWSYWLRPG–NH₂ |
| VIP (vasoactive intestinal peptide) | Immune & antimicrobial | 28 | Late-stage clinical trials | HSDAVFTDNYTRLRKQMAVKKYLNSILN–NH₂ |
By research area
- Tissue repair & signaling
Peptides studied in wound, tendon, gut and angiogenesis models.
ARA-290 (cibinetide), BPC-157, TB-500, Thymosin β4
- Immune & antimicrobial
Host-defence, thymic and anti-inflammatory peptides.
KPV, Larazotide, LL-37, Thymalin, Thymosin α1, VIP (vasoactive intestinal peptide)
- Growth hormone axis
GHRH analogues, ghrelin-receptor agonists and IGF-1 analogues.
CJC-1295, Follistatin-344, GHRP-2, GHRP-6, Hexarelin, IGF-1 LR3, Ipamorelin, MK-677 (ibutamoren), PEG-MGF, Sermorelin, Tesamorelin
- Metabolic & incretin
GLP-1, GIP, glucagon and amylin pathway compounds.
AOD-9604, Cagrilintide, Exenatide, Liraglutide, Mazdutide, Pramlintide, Retatrutide, Semaglutide, Survodutide, Tirzepatide
- Neuropeptides
Peptides studied in anxiety, cognition and sleep models.
Cerebrolysin, Dihexa, DSIP, Noopept, Selank, Semax
- Mitochondrial & ageing
Mitochondrial-derived, senolytic and bioregulator peptides.
Epitalon, FOXO4-DRI, Humanin, MOTS-c, Pinealon, SS-31 (elamipretide)
- Melanocortin & reproductive
Melanocortin-receptor agonists, kisspeptin and oxytocin.
Afamelanotide, Gonadorelin, Kisspeptin-10, Melanotan II, Oxytocin, PT-141 (bremelanotide), Setmelanotide, Triptorelin
- Cosmetic research
Peptides studied in skin and dermal-matrix models.
Argireline (acetyl hexapeptide-8), GHK-Cu, Matrixyl (palmitoyl pentapeptide-4), Snap-8
- Related non-peptides & cofactors
Compounds often catalogued alongside peptides.
5-Amino-1MQ, Glutathione, NAD+
- Bone & calcium
Parathyroid hormone analogues and calcitonin.
Abaloparatide, Calcitonin (salmon), Teriparatide